Investor Ideas #Potcasts 541, #Cannabis News and #Stocks on the Move; (TSXV: $KHRN.V) (TSX: $VIVO.TO) (TSX: $VLNS.TO) (OTCQX: $VLNCF) (TSXV: $PCLO.V)
Delta, Kelowna, BC, March 12, 2021 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/031221-StocksToWatch.mp3
Read this in full at https://www.investorideas.com/news/2021/cannabis-potcasts/03121KHRN-VIVO-VLNS-PCLO.asp
Hear the investor ideas potcast on Spotify
Hear Investor ideas cannabis potcast on iTunes
Today’s podcast overview/transcript:
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts.
In today’s podcast we look at a few public and private company announcements.
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF), a vertically integrated cannabis leader with core operations in Latin America and Europe, announced that the Company has successfully exported its registered Colombian cannabis strains, in the form of live clones, to Europe. This significant milestone represents the first shipment of medical cannabis live plant material to Europe from Colombia and is expected to accelerate access to European markets as the Company executes on its asset light growth strategy in the United Kingdom and Germany.
Through its EU-GMP certified supply chain partners in Europe, Khiron plans to introduce branded, cannabis-based medicinal products based on those already distributed by the Company in Colombia and Peru. Over the last year, more than 13,000 written prescriptions for extracts, formulated with Khiron´s registered cannabis strains, have been issued to patients in Latin America. As clinical evidence mounts, safety and efficacy data arising from Khiron's wholly-owned clinics in Latin America is expected to serve as a cornerstone of the Company's European medical education program.
Tejinder Virk, President of Khiron Europe, commented: "Our experience in Colombia and Europe tells us that doctors require solid clinical evidence to feel confident that medical cannabis is the right treatment for their patients. By exporting our Colombian cannabis strains, we will be able to bring our Latin American extracts to European patients, resulting in wider choices for doctors, and safer, more efficacious patient outcomes. Additionally, this import provides an opportunity to accelerate speed to market, optimize our global diversified supply chain and maximize economics."
Khiron's vertically integrated seed-to-patient business model is currently experiencing tremendous growth in Colombia. To date, Khiron medical cannabis products have shown strong evidence as alternative treatments for ailments such as chronic pain, anxiety, insomnia, depression, epilepsy, migraines, and Parkinson's Disease. With the proof of concept now validated in Colombia, the Company plans to build upon its success in new markets.
VIVO Cannabis Inc. (TSX: VIVO) (OTCQX: VVCIF) announced that its Vanluven facility in Napanee Ontario has received EU-GMP (European Union Good Manufacturing Practices) certification from Germany's Brandenburg health authority, the Landesamt für Arbeitsschutz, Verbraucherschutz und Gesundheit ("LAVG"). The certification takes effect immediately and enables VIVO, through its ABcann Medicinals subsidiary, to export product for sale into European and other markets requiring products to be manufactured under the rigorous GMP standards.
At the same time VIVO's German subsidiary Beacon Medical Germany GmbH received an import licence from the authority to import medical cannabis flowers from Napanee to Germany and the EU.
VIVO's President of European Operations, Andreas Sander said, "We are very excited about VIVO's receipt of GMP certification from the German health authority of the state of Brandenburg. This is a major step forward in VIVO's commitment to expand our medical cannabis business. It will allow us to start to provide patients, physicians and pharmacists with high quality medical cannabis flowers in Germany, the rest of Europe and beyond. It is a significant achievement that will help differentiate VIVO from many of its peers."
VIVO wants to thank the dedication of its GMP team for bringing this multi-year project to this successful milestone. GMP certification requires significant resources to achieve and to maintain. EU-GMP certification will likely provide VIVO the opportunity to pursue distribution opportunities not only in Germany but across the EU and in other global markets in which EU-GMP certification is required for market access. The Company is now working to achieve the first European sales of its Beacon Medical™ products, expected by Q3.
The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF), a leading manufacturer of cannabis products, announced that it has entered into a custom manufacturing agreement with Experion Biotechnologies Inc. (TSX-V: EXP) (OTCQB: EXPFF), a partner of the Company's recently acquired LYF Food Technologies Inc. Experion is a licensed cultivator, processor and brand builder with a portfolio of premium products.
Under the agreement, Valens will provide end-to-end pre-roll manufacturing and product distribution services to Experion – the Company's first custom manufacturing agreement of this nature following the receipt of its Health Canada licence amendment to sell dried cannabis products. In partnership, Valens and Experion will expand the pre-roll offering for Experion's popular Citizen Stash brand, which is focused on providing consumers the highest quality handcrafted, small batch cannabis.
"We are excited to kick off our pre-roll manufacturing services with the commencement of our agreement with Experion and expedite the entry of Valens-manufactured dried cannabis products into the Canadian market," said Tyler Robson, Chief Executive Officer, Co-Founder and Chair of The Valens Company. "Citizen Stash is synonymous with best-in-class products and we are proud to be chosen as a partner who can deliver on customized and premium quality products for the brand."
"We are pleased to work with Valens as this partnership will allow Experion to expand production to facilitate broader consumer access to our award-winning Citizen Stash products," stated Jarrett Malnarich, Chief Executive Officer of Experion Biotechnologies. "Partnering with an industry leader such as Valens allows us to immediately multiply our capacity and positions us to quickly develop next generation product lines. We believe this relationship demonstrates to the market that we are laser-focused on driving revenue by expanding our capacity to deliver premium cannabis products across Canada."
The terms of the agreement support a minimum two-year partnership with monthly minimum order quantities. Valens and Experion are in continued discussions to expand the existing agreement to include additional product development and custom manufacturing services for a range of next generation products beyond gummies, which are currently being manufactured at the LYF facility, and pre-rolls. There is, however, no assurance that any such deal would be reached.
PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., today provided an update on its operations in Mexico, in light of the country's continued advancement of legislation to legalize the use of recreational cannabis in the country. On March 10th, Mexico's Chamber of Deputies voted 316 to 129 to advance a bill that would legalize recreational cannabis use in the country (the "Bill"). This follows the move by Mexico's health ministry in January, to publish a much-anticipated legal framework for the medical cannabis space, including a provision for the import of medicinal extracts and products. Through PharmaCielo S.A. de C.V. ("PharmaCielo Mexico"), a joint venture with MINO Labs S.A. de C.V. ("MINO Labs"), a specialty pharmaceutical company and medical supply distributor based in Mexico, the Company is well-positioned to become a preferred supplier in the country.
Henning von Koss, CEO of PharmaCielo Ltd., commented, "Mexican cannabis legalization has had several stops and starts since 2018, but with the recent release of medicinal guidelines and Wednesday night's vote to continue advancing the Bill, the country looks poised to legalize and become the largest cannabis market in the world, sooner rather than later. PharmaCielo Mexico is positioned to become a preferred B2B supplier in the country, backed by PharmaCielo's broad extract portfolio, scale and flexibility, and MINO Labs' long track record of success in the market."
Manuel Cosme Odabachian, CEO of MINO Labs, added, "For more than 20 years, MINO Labs has been a leader in the Mexican specialty pharmaceutical distribution sector. The interest among our existing customer base for high quality cannabis extracts and value-added formulations has been growing as Mexican cannabis legalization has advanced over the past two years. We expect significant demand when the market opens and are very encouraged by the news that recreational cannabis legalization will continue to move forward, toward the April deadline provided by the Supreme Court."
PharmaCielo Mexico was established in 2019 to bring PharmaCielo's high-quality cannabis extracts and derivative products to the Mexican market, leveraging MINO Labs' extensive experience and broad presence in the country's pharmaceutical space. Following a Colombian site visit by MINO Labs in February 2021, PharmaCielo has submitted a request to initiate the Mexican GMP audit process, which the Company expects to be complete by the end of Q2'21, depending on the Mexican Authorities' availability. With the voting of the Bill, PharmaCielo Mexico will immediately initiate the process to obtain an import license for cannabis products in Mexico. PharmaCielo is currently producing extracts in compliance with EU-GMP guidelines.
Distribution of cannabis products by PharmaCielo in Mexico will be subject to the approval of the TSX Venture Exchange (the "TSXV").
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and that this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment.
Learn more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The Investorideas.com podcasts are also available on iTunes ( Apple Podcasts) , Audible , Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio , Google Play Music and most audio platforms available.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800 665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
